FACT BOOK 2016 年 9 月期. For the Fiscal Year Ended September 30, 2016 東証 1 部 (4554)

Transcription

1 FACT BOOK 6 年 月期 For the Fiscal Year Ended September, 6 東証 部 () TSE 貸借対照表 ( 連結 ) Consolidated Balance Sheet 損益計算書 ( 連結 ) 包括利益計算書( 連結 ) Consolidated Statements of Income and Comprehensive Income キャッシュ フロー計算書 ( 連結 ) Consolidated Statement of Cash Flows 株主資本等変動計算書 ( 連結 ) Consolidated Statement of Changes in Equity 貸借対照表 ( 単体 ) Nonconsolidated Balance Sheet 損益計算書 ( 単体 ) Nonconsolidated Statement of Income 株主資本等変動計算書 ( 単体 ) Nonconsolidated Statement of Changes in Equity 設備投資額 減価償却費 研究開発費の推移 Capital Expenditure, Depreciation and R&D Expenses 薬効分類別販売額 Sales Trend by Therapeutic Category 収益性指標 Profitability Indicators 効率性指標 Efficiency Indicators 安全性 その他指標 Stability & Indicators 株式情報 Stock Information 6 6 お問い合わせ先 Contact 富士製薬工業株式会社コーポレート企画部 Fuji Pharma Co., Ltd. Corporate Planning Department Phone:6 +6 Fax: fsk_ir@fujipharma.jp URL:

2 貸借対照表 ( 連結 ) Consolidated Balance Sheet as of September, 6 資産の部資産合計流動資産現金及び預金受取手形及び売掛金有価証券商品及び製品仕掛品原材料及び貯蔵品未収入金繰延税金資産その他貸倒引当金固定資産有形固定資産建物及び構築物減価償却累計額建物及び構築物 ( 純額 ) 機械装置及び運搬具減価償却累計額機械装置及び運搬具 ( 純額 ) 土地リース資産減価償却累計額リース資産 ( 純額 ) 建設仮勘定その他減価償却累計額その他 ( 純額 ) 無形固定資産のれんその他投資その他の資産投資有価証券長期前渡金繰延税金資産その他 Assets Total assets Current assets Cash and deposits Notes and accounts receivabletrade Securities Merchandise and finished goods Work in process Raw materials and supplies Accounts receivablesother Deferred tax assets Allowance for doubtful accounts Noncurrent assets Property, plant and equipment Buildings and structures Buildings and structures, net Machinery, equipment and vehicles Machinery, equipment and vehicles, net Land Leased assets Leased assets, net Construction in progress, net Intangible assets Goodwill Investments and other assets Investment securities Longterm advance payments Deferred tax assets FY/,, 6,,6,6,,,66,6,,,6,,,,6,,6, 6 6 FY/,,6,,6 6,,,6, 6,,6,6,,, 6,,6, 6, 6,,6,,6 6 6 FY/,,,, 6,6,, 6 6,,6,,,, 6,,,,6,,,6,66, 6 FY/6,, 6,,,6,6,6 6,,6,,,,66 6,,, 6,6,,6 6,6,6,,6, Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

3 貸借対照表 ( 連結 ) Consolidated Balance Sheet as of September, 6 負債の部負債合計流動負債支払手形及び買掛金短期借入金 年内返済予定の長期借入金リース債務未払法人税等賞与引当金役員賞与引当金返品調整引当金その他固定負債長期借入金リース債務退職給付引当金退職給付に係る負債その他 Liabilities Total liabilities Current liabilities Notes and accounts payabletrade Shortterm loans payable Current portion of longterm loans payable Lease obligations Income taxes payable Provision for bonuses Provision for directors' bonuses Provision for sales returns Noncurrent liabilities Longterm loans payable Lease obligations Provision for retirement benefits Net defined benefit liability FY/,,,6,6 6,,, FY/,, 6,6, 6,,6,6,,6 FY/,, 6, 6, 6,,, 6 FY/6,, 6,,,6 6,,6,, 純資産の部純資産合計株主資本資本金資本剰余金利益剰余金自己株式その他の包括利益累計額その他有価証券評価差額金繰延ヘッジ損益為替換算調整勘定退職給付に係る調整累計額非支配株主持分負債純資産合計 Net assets Total net assets Shareholders equity Capital stock Capital surplus Retained earnings Treasury shares Accumulated other comprehensive income Valuation difference on availableforsale securities Deferred gains or losses on hedges Foreign currency translation adjustment Remeasurements of defined benefit plans Minority interests Total liabilities and net assets,66,6,,6, 6 6,,,,,, 6,,,,,,66, 6,,6,,,,,, Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

4 損益計算書 ( 連結 ) 包括利益計算書 ( 連結 ) Consolidated Statements of Income and Comprehensive Income for the Fiscal Years ended September, 6 売上高売上原価売上総利益販売費及び一般管理費合計販売手数料給料及び賞与賞与引当金繰入額役員賞与引当金繰入額退職給付費用研究開発費減価償却費のれん償却費その他営業利益営業外収益為替差益生命保険配当金業務受託料その他営業外費用支払利息為替差損株式交付費その他経常利益特別利益固定資産売却益投資有価証券売却益補助金収入その他特別損失固定資産売却損固定資産除却損固定資産圧縮損税金等調整前当期純利益法人税 住民税及び事業税法人税等調整額法人税等合計当期純利益非支配株主に帰属する当期純利益親会社に帰属する当期純利益 Net sales Cost of sales Gross profit Selling, general and administrative expenses Sales commission Salaries and bonuses Provision for bonuses Provision for directors' bonuses Retirement benefit expenses Research and development expenses Depreciation Amortization of goodwill Operating income Nonoperating income Foreign exchange gains Dividend income of life insurance Fiduciary obligation fee Nonoperating expenses Interest expenses Foreign exchange losses Share issuance cost Ordinary income Extraordinary income Gain on sales of noncurrent assets Gain on sales of investment securities Subsidy income Extraordinary losses Loss on sales of noncurrent assets Loss on retirement of noncurrent assets Loss on reduction of noncurrent assets Income before income taxes and minority interests Income taxescurrent Income taxesdeferred Total income taxes Income before minority interests Minority interests in income FY/,,,,6,,6,,, ,6,,,6,6,6 FY/, 6,,,6,,,6 6,, 6 6, 6,,,,, FY/,6,,,,6,,,,, 6 6 6,,,, FY/6,,6,,6,,,,,6, 6 6,,6,,, 包括利益計算書 ( 連結 ) Consolidated Statement of Comprehensive Income 当期純利益その他の包括利益その他有価証券評価差額金繰延ヘッジ損益為替換算調整勘定退職給付に係る調整額包括利益 ( 内訳 ) 親会社株式に係る包括利益非支配株主に係る包括利益 Income before minority interests comprehensive income Valuation difference on availableforsale securities Deferred gains or losses on hedges Foreign currency translation adjustment Remeasurements of defined benefit plans, net of tax Comprehensive income Comprehensive income attributable to Comprehensive income attributable to owners of parent Comprehensive income attributable to minority interests FY/,6 6 6,, FY/, 6,66,66 FY/,,, FY/6, 6,, Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

5 キャッシュ フロー計算書 ( 連結 ) Consolidated Statement of Cash Flows for the Fiscal Years ended September, 6 営業活動によるキャッシュ フロー合計税金等調整前当期純利益減価償却費のれん償却費貸倒引当金の増減額 ( は減少 ) 賞与引当金の増減額 ( は減少 ) 役員賞与引当金の増減額 ( は減少 ) 退職給付引当金の増減額 ( は減少 ) 退職給付に係る負債の増減額 ( は減少 ) 受取利息及び受取配当金支払利息為替差損益 ( は益 ) 固定資産除却損売上債権の増減額 ( は増加 ) たな卸資産の増減額 ( は増加 ) 仕入債務の増減額 ( は減少 ) その他小計利息及び配当金の受取額利息の支払額法人税等の支払額投資活動によるキャッシュ フロー合計投資有価証券の取得による支出投資有価証券の売却による収入有形固定資産の取得による支出有形固定資産の売却による収入無形固定資産の取得による支出長期前渡金による支出子会社株式取得による支出補助金の受取額その他財務活動によるキャッシュ フロー合計自己株式の取得による支出短期借入金の純増減額 ( は減少 ) 長期借入れによる収入長期借入金の返済による支出株式の発行による収入配当金の支払額リース債務の返済による支出その他現金及び現金同等物に係る換算差額現金及び現金同等物の増減額 ( は減少 ) 現金及び現金同等物の期首残高現金及び現金同等物の期末残高 Net cash provided by (used in) operating activities Income before income taxes and minority interests Depreciation Amortization of goodwill Increase (decrease) in allowance for doubtful accounts Increase (decrease) in provision for bonuses Increase (decrease) in provision for directors' bonuses Increase (decrease) in provision for retirement benefits Increase (decrease) in net defined benefit liability Interest and dividend income Interest expenses Foreign exchange losses (gains) Loss on retirement of noncurrent assets Decrease (increase) in notes and accounts receivabletrade Decrease (increase) in inventories Increase (decrease) in notes and accounts payabletrade, net Subtotal Interest and dividend income received Interest expenses paid Income taxes paid Net cash provided by (used in) investing activities Purchase of investment securities Proceeds of investment securities Purchase of property, plant and equipment Proceeds from sales of property, plant and equipment Purchase of intangible assets Decrease (increase) in longterm advance payments Purchase of shares of subsidiaries resulting in change in scope of consolidation Subsidy income, net Net cash provided by (used in) financing activities Purchase of treasury shares Increase (decrease) in shortterm loans payable Proceeds from longterm loans payable Repayments of longterm loans payable Proceeds from issuance of common shares Cash dividends paid Repayments of lease obligations, net Effect of exchange rate change on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period FY/,6,, ,, 6,66 6,6,,6,,,,66 6, FY/,,,6,,6, 6, 6,,, 6,,6, 6,,6 FY/,,6 6 6,,6,,, 6,6,, 6,,6,66 FY/6,,, ,,, 6, 6, 6 6,,66 6, Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

6 株主資本等変動計算書 ( 連結 ) Consolidated Statement of Changes in Equity for the Fiscal Years ended September, 6 株主資本資本金当期首残高新株の発行当期変動額合計当期末残高資本剰余金当期首残高新株の発行当期変動額合計当期末残高利益剰余金当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額剰余金の配当親会社株主に帰属する当期純利益当期変動額合計当期末残高自己株式当期首残高当期変動額自己株式の取得自己株式の処分当期末残高株主資本合計当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額新株の発行剰余金の配当親会社株主に帰属する当期純利益自己株式の取得自己株式の処分当期変動額合計当期末残高その他の包括利益累計額その他有価証券評価差額金当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高繰延ヘッジ損益当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高為替換算調整勘定当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高退職給付に係る調整累計額当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高その他の包括利益累計額合計当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高非支配株主持分当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高純資産合計当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額新株の発行剰余金の配当親会社株主に帰属する当期純利益自己株式の取得自己株式の処分株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高 Shareholders' equity Capital stock Capital surplus Retained earnings Dividends of surplus Treasury shares Purchase of treasury shares Disposal of treasury shares Total shareholders' equity Dividends of surplus Purchase of treasury shares Disposal of treasury shares Accumulated other comprehensive income Valuation difference on availableforsale securities Net changes of items other than shareholders' equity Deferred gains or losses on hedges Net changes of items other than shareholders' equity Foreign currency translation adjustment Net changes of items other than shareholders' equity Remeasurements of defined benefit plans Net changes of items other than shareholders' equity Total accumulated other comprehensive income Net changes of items other than shareholders' equity Minority interests Net changes of items other than shareholders' equity Total net assets Dividends of surplus Purchase of treasury shares Disposal of treasury shares Net changes of items other than shareholders' equity FY/,,,6,6,,,6,,,,,,,, 6,,,66 Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.,,,6,, ,,,6,6,66 FY/,,,,,6,,,,,,,,,6,6,,,, ,66,66,,,, FY/,,,, 6,, 6, 6 6 6,, 6,,, FY/6,,,,,66 6, 6,,,,,, 6, 6,,6, ,, 6, 6,6

7 貸借対照表 ( 単体 ) Nonconsolidated Balance Sheet as of September, 6 資産の部資産合計流動資産現金及び預金受取手形売掛金有価証券商品及び製品仕掛品原材料及び貯蔵品前渡金前払費用繰延税金資産未収入金関係会社短期貸付金未収消費税等その他の流動資産貸倒引当金固定資産有形固定資産建物減価償却累計額建物 ( 純額 ) 構築物減価償却累計額構築物 ( 純額 ) 機械及び装置減価償却累計額機械及び装置 ( 純額 ) 車両運搬具減価償却累計額車両運搬具 ( 純額 ) 工具 器具及び備品減価償却累計額工具 器具及び備品 ( 純額 ) 土地リース資産減価償却累計額リース資産 ( 純額 ) 建設仮勘定無形固定資産販売権ソフトウエア電話加入権投資その他の資産投資有価証券関係会社株式出資金破産更生債権等長期前渡金長期前払費用繰延税金資産差入保証金保険積立金貸倒引当金 Assets Total assets Current assets Cash and deposits Notes receivabletrade Accounts receivabletrade Securities Merchandise and finished goods Work in process Raw materials and supplies Advance paymentstrade Prepaid expenses Deferred tax assets Accounts receivableother Shortterm loans receivable to subsidiaries and associates Consumption taxes receivable Allowance for doubtful accounts Noncurrent assets Property, plant and equipment Buildings Buildings, net Structures Structures, net Machinery and equipment Machinery and equipment, net Vehicles Vehicles, net Tools, furniture and fixtures Tools, furniture and fixtures, net Land Leased assets Leased assets, net Construction in progress Intangible assets Distributorship Software Telephone subscription right Investments and other assets Investment securities Shares of subsidiaries and associates Investments in capital Claims provable in bankruptcy, claims provable in rehabilitation and other Longterm Advance paymentstrade Longterm prepaid expenses Deferred tax assets Guarantee deposits Insurance funds Allowance for doubtful accounts FY/,,, 6,6 66,,,, 6,6,, 66,6,6,6 6, 6 6 FY/,,,,,6,66,6,6, 6,,6,6,,,, FY/,,6,,,,,6,6,,6,,,6,,,, 6,66 66 FY/ 6,,6 6,,66 6,6,, 6, 66,66,,6,,6,,,, 6,,,,,6 FY/,,,,6 6,,6, 6, 6,,6,6,6, 6,,,,,6,,,6 6 FY/6,, 6,,,,, 6,,,6,,,,,,, 6,6, 6,,6, 6 Copyright 6 Fuji Pharma Co., Ltd. All rights reserved. 6

8 貸借対照表 ( 単体 ) Nonconsolidated Balance Sheet as of September, 6 負債の部負債合計流動負債支払手形買掛金短期借入金 年内返済予定の長期借入金リース債務未払金未払費用未払法人税等未払消費税等預り金為替予約賞与引当金役員賞与引当金返品調整引当金その他固定負債長期借入金リース債務受入保証金退職給付引当金長期未払金その他 Liabilities Total liabilities Current liabilities Notes payabletrade Accounts payabletrade Shortterm loans payable Current portion of longterm loans payable Lease obligations Accounts payableother Accrued expenses Income taxes payable Accrued consumption taxes Deposits received Forward exchange contracts Provision for bonuses Provision for directors bonuses Provision for sales returns Noncurrent liabilities Longterm loans payable Lease obligations Guarantee deposits received Provision for retirement benefits Longterm accounts payableother FY/,,,, FY/,, 6,6,,6 6 6,, 6 FY/,,,6, 6,,,6 FY/,,6,,6 6,,6,, FY/ 6,,6,6, 6,,,6 FY/6,,,, 6, 6 6,,6,, 純資産の部純資産合計株主資本資本金資本剰余金資本準備金その他資本剰余金利益剰余金利益準備金別途積立金繰越利益剰余金自己株式評価 換算差額等 その他有価証券評価差額金 繰延ヘッジ損益負債純資産合計 Net assets Total net assets Shareholders equity Capital stock Capital surplus Legal capital surplus capital surplus Retained earnings Legal retained earnings General reserve Retained earnings brought forward Treasury shares Valuation and translation adjustments Valuation difference on availableforsale securities Deferred gains or losses on hedges Total liabilities and net assets,6,6,,6,6 6, 6,,,,,,,6,6 6, 6,,,,,,,6,6 6,6 6,, 6 6,,,,,, 6,6 6,, 6,,,,,, 6, 6,,,,,6,6,,, 6, 6,,,, Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

9 損益計算書 ( 単体 ) Nonconsolidated Statement of Income for the Fiscal Years ended September, 6 売上高売上原価売上総利益販売費及び一般管理費合計販売促進費販売手数料荷造運搬費交際費役員報酬給料及び賞与賞与引当金繰入額役員賞与引当金繰入額貸倒引当金繰入額退職給付費用福利厚生費旅費及び交通費賃借料減価償却費研究開発費その他営業利益営業外収益受取利息有価証券利息受取配当金為替差益生命保険配当金受取手数料助成金収入受取補償金業務受託料その他営業外費用支払利息株式交付費株式公開費用為替差損売上割引その他経常利益特別利益投資有価証券売却益補助金収入特別損失固定資産売却損固定資産除却損固定資産圧縮損退職給付費用投資有価証券評価損災害による損失本社移転費用 Net sales Cost of sales Gross profit Selling, general and administrative expenses Promotion expenses Sales commission Packing and transportation expenses Entertainment expenses Directors' compensations Salaries and bonuses Provision for bonuses Provision for directors' bonuses Provision of allowance for doubtful accounts Retirement benefit expenses Welfare expenses Traveling and transportation expenses Rent expenses Depreciation Research and development expenses Operating income Nonoperating income Interest income Interest on securities Dividend income Foreign exchange gains Dividend income of life insurance Commission fee Subsidy income Compensation income Fiduciary obligation fee Nonoperating expenses Interest expenses Share issuance cost Going public expenses Foreign exchange losses Sales discounts Ordinary income Extraordinary income Gain on sales of investment securities Subsidy income Extraordinary losses Loss on sales of noncurrent assets Loss on retirement of noncurrent assets Loss on reduction of noncurrent assets Retirement benefit expenses Loss on valuation of investment securities Loss on disaster Head office transfer cost Loss on adjustment for changes of accounting standard for asset retirement obligations FY/,6,, 6, 6,,6,6 6, 6 FY/,,, 6, 6, 6,,6 6,6 6 FY/,,,66,, 6,6,, 6 6, FY/,,,,66, 6, 6,6,6, 6 6 6, 6 6 FY/,,6,,,6 6, 6, 6,, FY/6,,,,, 6, 6,,, 6 6, 資産除去債務会計基準の適用に伴う影響額 その他税引前当期純利益法人税 住民税及び事業税法人税等調整額法人税等合計当期純利益 Income before income taxes Income taxescurrent Income taxesdeferred Total income taxes,6,6,,,,,,,,,,,,,,,6, 6 6,6 Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

10 株主資本等変動計算書 ( 単体 ) Nonconsolidated Statement of Changes in Equity for the Fiscal Years ended September, 6 株主資本資本金当期首残高当期変動額新株の発行当期変動額合計当期末残高資本剰余金資本準備金当期首残高当期変動額新株の発行当期変動額合計当期末残高その他資本剰余金当期首残高当期変動額当期末残高資本剰余金合計当期首残高当期変動額新株の発行当期変動額合計当期末残高利益剰余金利益準備金当期首残高当期変動額当期末残高その他利益剰余金別途積立金当期首残高当期変動額当期末残高繰越利益剰余金当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額剰余金の配当当期純利益当期変動額合計当期末残高利益剰余金合計当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額剰余金の配当当期純利益当期変動額合計当期末残高自己株式当期首残高当期変動額自己株式の取得自己株式の処分当期変動額合計当期末残高株主資本合計当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額新株の発行剰余金の配当当期純利益自己株式の取得自己株式の処分当期変動額合計当期末残高 Shareholders equity Capital stock Capital surplus Legal capital surplus capital surplus Total capital surplus Retained earnings Legal retained earnings retained earnings General reserve Retained earnings brought forward Dividends of surplus Total retained earnings Dividends of surplus Treasury shares Purchase of treasury shares Disposal of treasury shares Total shareholders equity Dividends of surplus Purchase of treasury shares Disposal of treasury shares FY/ FY/ FY/ FY/6,,,6,6 6 6,6,6 6 6,,,,,,,,,,,,6,,,,,,,,,,6,,, 6 6,6,,, 6 6,,,,,,,,6,6,,,6,,,,,,,,,, 6 6,, 6 6,,,,6 6,6,,,6,6 6,6,,,,,,, 6,6,,,,,, 6 6,, 6 6,,,, 6,6,,,, 6,6,,,,,, 6,6,,6 Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

11 評価 換算差額等その他有価証券評価差額金当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高繰延ヘッジ損益当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高評価 換算差額等合計当期首残高当期変動額株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高純資産合計当期首残高会計方針の変更による累積的影響額会計方針の変更を反映した当期首残高当期変動額新株の発行剰余金の配当当期純利益自己株式の取得自己株式の処分株主資本以外の項目の当期変動額 ( 純額 ) 当期変動額合計当期末残高 Valuation and translation adjustments Valuation difference on availableforsale securities Net changes of items other than shareholders equity Deferred gains or losses on hedges Net changes of items other than shareholders' equity Total valuation and translation adjustments Net changes of items other than shareholders equity Total net assets Dividends of surplus Purchase of treasury shares Disposal of treasury shares Net changes of items other than shareholders equity FY/ ,,, 6,6, FY/ ,,,, 6,, FY/,, 6,6,, FY/6,, 6,6,,6 Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

12 設備投資額 減価償却費 研究開発費の推移 Capital Expenditure, Depreciation and R&D Expenses 設備投資額 * 減価償却費 研究開発費の推移 Capital Expenditure *, Depreciation and R&D Expenses FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 設備投資額減価償却費研究開発費 Capital Expenditure Depreciation R&D Expenses,,,6,6,, 単体 連結 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated,,,,6,6,,,6,,6,6 6,,,6,6, 6,,,,66, * 設備投資額には 有形固定資産 ソフトウェアの取得額及びリース契約による取得価額相当額を含みます *Capital expenditure includes acquisition cost of property, plant and equipment, and software; and acquisition cost equivalents of lease agreement. 設備投資額 研究開発費の推移 設備投資額 Capital Expenditure Capital Expenditure and R&D Expenses 研究開発費 R&D Expenses,,,,,,,,6,6,,,6,,, FY/ FY/ FY/ 6 FY/ FY/ 6 FY/6 * 年 月期よりタイの関連会社が連結対象に加わっているため 同期以降は 単体と連結の数字を表示しています 時系列比較の際はご注意いただきますようお願いいたします なお グラフ中の数値は 単体ベースで表示しています *Nonconsolidated and consolidated figures are presented for FY/ onwards, as an affiliated company in Thailand was included in the scope of consolidation in FY/, and it should be noted when making a yearonyear comparison. Figures in the graphs are shown on a nonconsolidated basis. Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

13 薬効分類別販売額 Sales Trend by Therapeutic Category 売上高製品診断用薬ホルモン剤代謝性医薬品循環器官用薬抗生物質及び化学療法剤泌尿 生殖器官系用薬外皮用薬その他商品ホルモン剤診断用薬体外診断用医薬品その他合計 ( 製品 + 商品 ) 診断用薬ホルモン剤代謝性医薬品循環器官用薬体外診断用医薬品抗生物質及び化学療法剤泌尿 生殖器官系用薬外皮用薬その他 Net sales Finished goods Diagnostic drugs Hormone drugs Metabolic drugs Circulatory drugs Antibiotics and chemotherapeutics Urogenital and genital organ drugs Dermatological preparations s Merchandise Hormone drugs Diagnostic drugs In vitro diagnostics s Total (finished goods + merchandise) Diagnostic drugs Hormone drugs Metabolic drugs Circulatory drugs In vitro diagnostics Antibiotics and chemotherapeutics Urogenital and genital organ drugs Dermatological preparations s FY/,6,6,,6,6,,6,,6, 6,,,6,66 FY/ FY/ * FY/ * FY/ * FY/6 * 単体連結単体連結単体連結単体連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated,,,,6, 6 6,,, 6,,,, ,,,,,, 6 6,,,,,,, 6,66,,6,,, 6 6,,,,,,, 6,,,6,,,6,6 6,,,6 6,,66,,,,,,,,6, 6,,,6 6,,66,,,6,,,,, 6,,, 66 6,,,, 6,6,6 6,,,, 6,,, 66 6,6,,, 6,,,,6 6,,, 6,6 6,,6,,,,,, 6 6,,,,6 6,,, 6,6 6,,6,,,,,, 6 6, 薬効分類別販売実績の構成比 Sales Component Ratio by Therapeutic Category 診断用薬 Diagnostic Drugs ホルモン剤 Hormone Drugs 代謝性医薬品 Metabolic drugs 循環器官用薬 Circulatory Drugs 体外診断用薬品 In vitro Diagnostics 抗生物質及び化学療法剤 Antibiotics and Chemotherapeutics 泌尿 生殖器官系用薬 Urogenital and Genital Organ Drugs 外皮用薬 Dermatological Preparations その他 s FY/6.%.%.%.%.%.%.%.%.% FY/.%.%.% 6.%.%.%.%.6%.% FY/ FY/ FY/ FY/.%.% 6.%.6%.%.%.%.6%.%.%.%.%.%.%.%.%.%.6%.%.%.%.%.%.%.%.%.%.%.%.%.%.%.%.%.%.% % % % 6% % % 剤形 Drug Category 注射剤 Parenteral Injections 経口剤 Oral Medications 外用剤 External Applications 体外診断薬 Diagnostic Agents 薬効別主要取扱製品 薬効分類 Therapeutic Category 診断用薬 Diagnostic drugs 代謝性医薬品 Metabolic drugs ホルモン剤 Hormone drugs ホルモン剤 Hormone drugs 代謝性医薬品 Metabolic drugs ホルモン剤 Hormone drugs 外皮用薬 Dermatological preparations 体外診断用医薬品 In vitro diagnostics Mainstay Pharmaceuticals by Therapeutic Category 主要取扱製品 Main Products オイパロミン R 注 イオパーク R 注 オプチレイ R 注 マグネスコープ R 静注 OYPALOMIN injection, IOPAQUE injection, OPTIRAY injection, Magnescope intravenous injection フィルグラスチム BS 注シリンジ Filgrastim BS injection Syringe HMG 筋注用 デキサート R 注射液 HMG intramuscular injection, DEXART injection ルナベル R 配合錠 クロミッド R 錠 ファボワール R 錠 LUNABELL tablets, CLOMID tablets, FAVOIR tablets リマプロストアルファデクス錠 LIMAPROST ALFADEX tablets ブセレキュア点鼻液 ナファレリール点鼻液 ウトロゲスタン R 腟用カプセル BUSERECUR, NAFARELIL, UTROGESTAN Vaginal Capsules mg デキサン VG 軟膏 エルタシン軟膏 DEXANVG ointment, ELTACIN ointment クリアビュー Influenza A/B クリアプラン ファインビジョン Influenza Clearview Exact Influenza A&B, CLEARPLAN, FineVision Influenza * 年 月期よりタイの関連会社が連結対象に加わっているため 同期以降は 単体と連結の数字を表示しています 時系列比較の際はご注意いただきますようお願いいたします なお グラフ中の数値は 単体ベースで表示しています *Nonconsolidated and consolidated figures are presented for FY/ onwards, as an affiliated company in Thailand was included in the scope of consolidation in FY/, and it should be noted when making a yearonyear comparison. Figures in the graphs are shown on a nonconsolidated basis. Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

14 収益性指標 Profitability Indicators FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 売上高 Net Sales,6, 単体 Nonconsolidated, 連結 Consolidated, 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated,,,,6,, 売上原価 Cost of Sales,,,,, 6,,6,,,6 売上総利益 Gross Profit,,,66,,,,,,, 販売費及び一般管理費 SG&A Expenses 6, 6,,,6,66,6,,,,6 うち 研究開発費 R&D Expenses,6,,,,6,6,,,, 営業利益 Operating Income,6,6,,6,,,,,,6 経常利益 Ordinary Income,,6,,6,,,,,, 当期純利益 Net Income,,,,6,,,6,,6, 収益性指標売上総利益率販売管理費率研究開発費率営業利益率経常利益率当期純利益率 Profitability Indicators Gross Profit on Sales SG&A Expenses Ratio R&D Expenses Ratio Operating Income Margin Ordinary Income Margin Net Income Margin FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 単体 連結 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated.6%.%.% 6.% 6.%.%.%.% 6.%.%.% 6.%.%.%.%.%.%.%.%.%.%.%.%.%.%.% 6.%.%.%.%.%.% 6.%.%.%.%.%.%.%.%.%.%.%.%.%.%.% 6.6%.%.%.%.%.% 6.%.6%.%.%.%.% 6.% ( 百万円 / Million),,,,,,, 売上総利益率 Gross Profit on Sales ( 百万円 / Million), 6,,, 販売管理費率 SG&A Expenses Ratio 売上高 売上総利益 売上総利益率 販売管理費及び一般管理費 販売管理費率 Net Sales Gross Profit Gross Profit on Sales SG&A Expenses SG&A Expenses Ratio.6% %,.%.%.%.%.% 6 % % % % %.%.%.%.%.%.% % % % % % FY/ FY/ FY/ FY/ 研究開発費率 FY/ FY/6 営業利益率 当期純利益率 ( 百万円 / Million) R&D Expenses Ratio ( 百万円 / Million) Operating Income Margin / Net Income Margin 営業利益当期純利益営業利益率当期純利益率研究開発費研究開発費率 Operating Net Income Operating Net Income R&D Expenses R&D Expenses Ratio Income Income Margin Margin, %, 6.% %,6,.% 6.%.% 6.%.%.% 6 % % % 6% % % % % %,,,,,, FY/.% FY/.% 6.% FY/.%.% FY/.% FY/.%.%.% FY/6.% 6.% % 6% % % % % 6% % FY/ FY/ FY/ FY/ FY/ FY/6 % FY/ FY/ FY/ FY/ FY/ FY/6 % * 年 月期よりタイの関連会社が連結対象に加わっているため 同期以降は 単体と連結の数字を表示しています 時系列比較の際はご注意いただきますようお願いいたします なお グラフ中の数値は 単体ベースで表示しています *Nonconsolidated and consolidated figures are presented for FY/ onwards, as an affiliated company in Thailand was included in the scope of consolidation in FY/, and it should be noted when making a yearonyear comparison. Figures in the graphs are shown on a nonconsolidated basis. Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

15 効率性指標 Efficiency Indicators FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 単体 Nonconsolidated 連結 Consolidated 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated 総資産回転率 ( 回 ) 流動資産回転率 ( 回 ) 固定資産回転率 ( 回 ) Total Assets Turnover (times) Current Assets Turnover (times) Fixed Assets Turnover (times) 在庫回転日数 ( 日 ) Inventories Turnover (days) 売上債権回転日数 ( 日 ) Accounts Receivable Turnover (days) 仕入債務回転日数 ( 日 ) Accounts Payable Turnover (days) FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 単体 連結 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated 総資産回転率 = 売上高 / 総資産 ( 期中平均 ) 流動資産回転率 = 売上高 / 流動資産 ( 期中平均 ) 固定資産回転率 = 売上高 / 固定資産 ( 期中平均 ) Total Assets Turnover = Net Sales/Average Total Assets Current Assets Turnover = Net Sales/Average Current Assets Fixed Assets Turnover = Net Sales/Average Noncurrent Assets 在庫回転日数 =( 棚卸資産 ( 期中平均 )/ 売上高 ) 6 売上債権回転日数 =( 売上債権 ( 期中平均 )/ 売上高 ) 6 仕入債務回転日数 =( 仕入債務 ( 期中平均 )/ 売上高 ) 6 Inventories Turnover = Average Inventories/Net Sales x 6 Accounts Receivable Turnover = Average Accounts Receivable/Net Sales x 6 Accounts Payable Turnover = Average Accounts Payable/Net Sales x 6 流動資産回転率 Current Assets Turnover 固定資産回転率 Fixed Assets Turnover ( 回 /Times) ( 回 /Times)....6 回... 回. 回.6 回. 回.6 回... 回. 回. 回. 回. 回.. 回. FY/ FY/ FY/ FY/ / 期 6/ 期. FY/ FY/ FY/ FY/ FY/ FY/6 在庫回転日数 Inventories Turnover ( 日 /Days) ( 日 /Days). 日. 日 売上債権回転日数 Accounts Receivable Turnover 6. 日 6. 日.6 日 6. 日 6. 日. 日. 日. 日. 日. 日 FY/ FY/ FY/ FY/ / 期 6/ 期 FY/ FY/ FY/ FY/ FY/ FY/6 * 年 月期よりタイの関連会社が連結対象に加わっているため 同期以降は 単体と連結の数字を表示しています 時系列比較の際はご注意いただきますようお願いいたします なお グラフ中の数値は 単体ベースで表示しています *Nonconsolidated and consolidated figures are presented for FY/ onwards, as an affiliated company in Thailand was included in the scope of consolidation in FY/, and it should be noted when making a yearonyear comparison. Figures in the graphs are shown on a nonconsolidated basis. Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

16 安全性 その他指標 Stability & Indicators 自己資本 Equity 総資産 Total Assets 流動資産 Current Assets 固定資産 Noncurrent Assets 流動負債 Current Liabilities 有利子負債 ( 借入 ) InterestBearing Debt (loans payable) FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 単体 連結 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated,6,,,,,,,,,6,,,,,6,6,,,66,,,66, 6,, 6,,6,66,6,,,,6,,,6,,,,,6,6,,,,,,6,6,,,,,,,,,,, FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 単体 連結 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated 自己資本比率 Equity Ratio.%.% 6.% 6.% 6.%.% 6.% 6.% 6.% 6.% 流動比率 Current Ratio.6%.%.% 66.6%.% 6.%.6%.%.%.6% 固定比率 Fixed Ratio.%.% 6.% 6.%.%.6%.%.%.6%.% 自己資本利益率 (ROE) Return on Equity (ROE).% 6.%.%.6%.%.%.%.%.%.% 総資産経常利益率 (ROA) Return on Total Assets (ROA).%.%.%.6%.% 6.%.% 6.%.% 6.% ( 百万円 / Million),,, 自己資本 Equity.%.% 自己資本比率 Equity Ratio 総資産 Total Assets 自己資本比率 Equity Ratio 6.% 6.% 6.% 6.% % % 6% ( 百万円 / Million),,,,.6% 流動資産 Current Assets.% 流動比率 Current Ratio 流動負債 Current Liabilities 流動比率 Current Ratio.%.%.6%.% % % % %, %, %, %,, % % FY/ FY/ FY/ FY/ FY/ FY/6 % FY/ FY/ FY/ FY/ FY/ FY/6 % ( 百万円 / Million) 自己資本 Equity, 固定比率 Fixed Ratio 固定資産 Noncurrent Assets 固定比率 Fixed Ratio % % 自己資本利益率 (ROE) Return on Equity (ROE).% ROE ROA ROE / ROA 総資産経常利益率 (ROA) Return on Total Assets (ROA),,,.%.% 6.%.%.%.6% % 6% % % %.%.% 6.%.%.%.%.%.%.%.%.% 6, % FY/ FY/ FY/ FY/ FY/ FY/6 % % FY/ FY/ FY/ FY/ FY/ FY/6 * 年 月期よりタイの関連会社が連結対象に加わっているため 同期以降は 単体と連結の数字を表示しています 時系列比較の際はご注意いただきますようお願いいたします なお グラフ中の数値は 単体ベースで表示しています *Nonconsolidated and consolidated figures are presented for FY/ onwards, as an affiliated company in Thailand was included in the scope of consolidation in FY/, and it should be noted when making a yearonyear comparison. Figures in the graphs are shown on a nonconsolidated basis. Copyright 6 Fuji Pharma Co., Ltd. All rights reserved.

17 株式情報 Stock Information 株当たり指標 ( 単位 : 円 ) Indicators per Share ( ) 6 年 月 日現在 As of September, 6 FY/ FY/ FY/ * FY/ * FY/ * FY/6 * 単体 連結 単体 連結 単体 連結 単体 連結 Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated Nonconsolidated Consolidated 期末株価 Share Price at Termend,66,6,,,,6 株当たり当期純利益 (EPS) Net Income per Share 株当たり純資産 (BPS) Net Assets per Share 6.6,6..,6..,6. 6.,.6.,..,6..6,..,..,..6,.6 株当たり配当金 Dividend per Share......予定 大株主の状況 ( 上位 社 ) Major Shareholders (Top Shareholders) 6 年 月 日現在 As of September, 6 所有株式数 ( 株 ) Number of Shares 所有株式の割合 (%) Shareholding Ratio 三井物産株式会社 MITSUI & CO., LTD.,,.% 有限会社 FJP FJP Ltd.,66,.6% 今井 博文 Hirofumi Imai,6,.% 新井 規子 Noriko Arai 6,.% 日本トラスティ サービス信託銀行株式会社 ( 信託口 ) Japan Trustee Services Bank, Ltd. (Trust Account),.% BBH FOR FIDELITY LOWPRICED STOCK FUND (PRINCIPAL ALL SECTOR SUBPORTFOLIO),6.6% 今井 道子 Michiko Imai,.% RBC IST PCT NON LENDING ACCOUNT,.% 日本マスタートラスト信託銀行株式会社 ( 信託口 ) NORTHERN TRUST CO. (AVFC) REHCROO The Master Trust Bank of Japan, Ltd. (Trust Account),,.%.% 自己株式 6,6 株は 上記大株主から除外しております Note: The 6,6 shares of treasury shares held by Fuji Pharma are not included in the above list of major shareholders. 所有者別株式保有の状況 Shareholding by Category 6 年 月 日現在 As of September, 6 FY/6 FY/ FY/ 個人その他 Individuals and 外国法人等 金融機関 証券会社 その他国内法人 自己株式 Foreign Institutions and s Financial Institutions Securities Companies Japanese Companies Treasury Shares.6%.66%.%.%.6%.%.%.%.%.%.%.%.%.6% 6.%.6%.%.6% FY/.6%.6%.%.%.6% FY/.%.%.%.6% % % % 6% % % * 年 月期よりタイの関連会社が連結対象に加わっているため 同期以降は 単体と連結の数字を表示しています *Nonconsolidated and consolidated figures are presented for FY/ onwards, as an affiliated company in Thailand was included in the scope of consolidation in FY/. Copyright 6 Fuji Pharma Co., Ltd. All rights reserved. 6